Article Figures & Data
Figures
- Fig. 1.
Treatment effect of CEP-751 on NBL cell lines grown in nude mice. A, IMR-5; B, CHP-134; C, NBL-S therapeutic studies; D, IMR-5 prevention study results; E and F, CHP-134 prevention study comparing the treatment effect of six early- and six late-appearing tumors (see Table 1<$REFLINK> ). Bars, SE.
- Fig. 2.
Treatment effect of CEP-751 on 2 MBL cell lines grown in nude mice. Therapeutic studies: A, D341; B, D283. Prevention study: C, D341. Bars, SE. (See Table 2<$REFLINK> .)
- Fig. 3.
Treatment effect of CEP-751 on SY5Y NBL cells (A) and two TrkB transfected clones, SY5Y-G8 (B) and SY5Y-G12 (C).
- Fig. 4.
Effect of compound on apoptosis in CHP134 tumors obtained after 1, 3, and 5 days of treatment. Left (from top to bottom), DAPI stained tumor cells on days 2, 4, and 6. Right (from top to bottom), TUNEL stained tumor cells on days 2, 4, and 6. The second and third rows show progressive increase in apoptotic cells with time, as detected by the TUNEL assay, in CEP-751 treated tumors.
Tables
- Table 1
In vivo studies of NBL
Tumor size (cm3) Analysis of slopea Cell line Day of analysis Compound Control Compound Control A. Neuroblastoma therapeutic studiesb IMR-5 12 1.96 ± 0.35 (n = 5) 3.91 ± 1.22 (n = 5) 0.17 ± 0.051 (n = 5) 0.28 ± 0.109 (n = 5) P = 0.025 P = 0.024 CHP 134 15 1.9 ± 0.75 (n = 4) 4.5 ± 0.98 (n = 3) 0.151 ± 0.055 (n = 6) 0.299 ± 0.068 (n = 5) P = 0.034 P = 0.12 NBL-S 17 0.94 ± 0.24 (n = 5) 5.2 ± 2.46 (n = 4) 0.15 ± 0.034 (n = 5) 0.264 ± 0.014 (n = 4) P = 0.016 P = 0.12 B. Neuroblastoma prevention studiesc IMR-5 27 1.3 ± 1.63 (n = 7) 2.7 ± 1.55 (n = 6) 0.118 ± 0.036 (n = 7) 0.188 ± 0.041 (n = 6) P = 0.062 P = 0.073 CHP 134 (combined) See text 0.064 ± (n = 6) 0.122 ± (n = 6) P = 0.058 CHP 134 (early) 29 See text 0.148 ± 0.013 (n = 3) 0.169 ± 0.01 (n = 3) P = 0.28 CHP 134 (late) 58 See text 0.022 ± 0.011 (n = 3) 0.140 ± 0.009 (n = 3) P = 0.049 -
a Figures given for the average daily growth rate.
-
b Treatment started after tumors measured >0.24 g.
-
c Treatment commenced prior to tumor appearance.
-
- Table 2
In vivo studies of MBL
Tumor size (cm3) Analysis of slopea Cell line Day of analysis Compound Control Compound Control A. Medulloblastoma therapeutic studiesb D341 15 1.98 ± 1.86 (n = 5) 2.24 ± 0.790 (n = 5) 0.199 ± 0.091 (n = 6) 0.238 ± 0.068 (n = 6) P = 0.60 P = 0.75 DAOY 16 1.51 ± 0.689 (n = 5) 1.97 ± 0.603 (n = 3) 0.152 ± 0.045 (n = 5) 0.151 ± 0.069 (n = 3) P = 0.39 P = 0.96 D283 39 1.044 ± 0.297 (n = 8) 1.54 ± 0.51 (n = 8) 0.017 ± 0.008 (n = 8) 0.031 ± 0.012 (n = 8) P = 0.031 P = 0.021 B. Medulloblastoma prevention studyc D341 16 0.91 ± 0.92 (n = 5) 2.17 ± 1.42 (n = 6) 0.092 ± 0.072 (n = 8) 0.186 ± 0.039 (n = 9) P = 0.10 P = 0.126 -
a Figures given for the average daily growth rate.
-
b Treatment started after tumors measured >0.24 g.
-
c Treatment commenced prior to tumor appearance.
-
Volume 5, Issue 11
